271 related articles for article (PubMed ID: 25405759)
21. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
[TBL] [Abstract][Full Text] [Related]
22. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
[TBL] [Abstract][Full Text] [Related]
24. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.
Kirtek T; Chen W; Laczko D; Bagg A; Koduru P; Foucar K; Venable E; Nichols M; Rogers HJ; Tam W; Orazi A; Hsi ED; Hasserjian RP; Wang SA; Arber DA; Weinberg OK
Leuk Res; 2023 Jul; 130():107309. PubMed ID: 37210875
[TBL] [Abstract][Full Text] [Related]
25. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
26. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
27. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
[TBL] [Abstract][Full Text] [Related]
28. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
29. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
30. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
31. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
Haferlach C; Dicker F; Herholz H; Schnittger S; Kern W; Haferlach T
Leukemia; 2008 Aug; 22(8):1539-41. PubMed ID: 18528419
[TBL] [Abstract][Full Text] [Related]
33. Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
Abramowitz J; Neuman T; Perlman R; Ben-Yehuda D
BMC Med Genomics; 2017 Mar; 10(1):18. PubMed ID: 28340577
[TBL] [Abstract][Full Text] [Related]
34. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
35. Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.
Feurstein S; Rücker FG; Bullinger L; Hofmann W; Manukjan G; Göhring G; Lehmann U; Heuser M; Ganser A; Döhner K; Schlegelberger B; Steinemann D
BMC Genomics; 2014 Sep; 15(1):784. PubMed ID: 25213837
[TBL] [Abstract][Full Text] [Related]
36. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.
Cazzola A; Schlegel C; Jansen I; Bochtler T; Jauch A; Krämer A
Leukemia; 2019 Nov; 33(11):2619-2627. PubMed ID: 31444400
[TBL] [Abstract][Full Text] [Related]
37. Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
Novak ER; Deshpande A; Finlay D; Mason JR; Deshpande AJ; Adams PD; Li S
Methods Mol Biol; 2023; 2594():87-95. PubMed ID: 36264490
[TBL] [Abstract][Full Text] [Related]
38. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
40. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]